New
HealthMore in Health→
Five-Year Trial Finds Lasting Melanoma Benefit for Relatlimab-Nivolumab
Key Takeaways
- Five-year RELATIVITY-047 data compare relatlimab plus nivolumab with nivolumab alone.
- The combination improved progression-free, overall and melanoma-specific survival in the reported analysis.
- The safety profile was reported as consistent with prior findings.
DE
DT Editorial Team··via nature.com